HomeAntitrust Chronicle® 2014Spring 2014, Volume 4, Number 2

Spring 2014, Volume 4, Number 2

Antitrust Chronicle - Patents Drugs and Antitrust April II

Antitrust Chronicle® – Patents, Drugs & Antitrust

This issue looks at four health issues recently argued by the FTC. First, we deal with the FDA’s REMS (risk evaluation and mitigation strategies) program and how it seems to conflict with the FTC’s desire to encourage generic competition. The FTC is examining branded pharmaceutical firms’ refusal to sell samples of restricted distribution products to firms seeking approval to market generic versions. The contributing authors ask some relevant questions such as — under which circumstances a monopolist’s refusal to deal with a rival constitutes exclusionary conduct that violates Section 2 of the Sherman Act? whether there is merit in using antitrust laws to force brand-name drug companies to share samples of their products with generic rivals to further competition and reduce the cost of prescription drugs, or is congressional action a better route?

In this Issue

In Case You Missed It

March 2021 - I

Antitrust Chronicle 2021 Antitrust Horizons Cover March

March - Special Edition

Towards a Competition Enabling Framework in Asia Pacific Antitrust Chronicle - March 2021

February 2021 - II

Antitrust Chronicle - Gatekeepers

Chronicles by Year

Most Read Articles

Enable Notifications    OK No thanks